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Objectives. We evaluated the endothelial and vascular smooth 
muscle function in patients with chronic severe anemia to deter- 
mine whether increased basal nitric oxide levels contribute to the 
systemic vasodilation and high cardiac output seen in these 
patients. 
Background. Patients with chronic severe anemia have a high 
output state due to a low systemic vascular esistance. However, 
the cause of the low vascular esistance is unclear. Because hemo- 
globin is a potent inhibitor of endothelium.derived r laxing factor, 
we postulated that in chronic severe anemia, low circulating 
hemoglobin results in reduced inhibition of endothelium-derived 
relaxing factor. The basal endothelium-derived relaxing factor 
activity therefore increases, and this contributes ignificantly to 
the low systemic vascular esistance and the hyperdynamic state 
seen in this condition. 
Methods. Hemodynamic variables and forearm blood flow 
(using plethysmography) were measured in eight patients with 
chronic severe anemia before (hematocrit 16 -+ 2% [mean -+ SD]) 
and within 24 h of red blood cell transfusion (n = 6, hematocrit 
30 + 1%) and in six control subjects. The effect on baseline blood 
flow of blocking endothelium.derived r laxing factor activity with 
N~-monomethyI-L-arginine was investigated. In addition, the 
effects of both endothelium-dependent and endothelium- 
independent vasodilators on forearm blood flow were tested. 
Results. Baseline forearm blood flow was markedly increased in 
untreated patients (6.5 -+ 1.2 ml/min per 100 ml) compared with 
that in control subjects (2.8 +- 0.7 ml/min per 100 ml, p < 0.0001. 
95% confidence interval [CI] for difference -5  to -2.5). Red blood 
cell transfusion significantly reduced blood flow in the anemic 
patients to 3.5 -+ 1.1 ml/min per 100 ml (p < 0.001, 95% CI for 
difference -4.9 to -1.9), which was not significantly different 
from that in control subjects; increased systemic vascular esis- 
tance (796 + 141 to 1,230 +- 151 dynes.s.cm -s, p < 0.001); and 
decreased cardiac output (4.9 -+ 0.6 to 3.5 +- 0.5 liters/min per m 2, 
p < 0.001). NG-monomethyl-L-arginine (16/~mol/min), a specific 
inhibitor of endothelium-derived r laxing factor, reduced forearm 
blood flow by an equal amount (p = 0.9, 95% CI for difference 
-0.7 to 0.8) in control subjects (0.98 + 0.39 ml/min) and treated 
patients (1.03 -+ 0.8 ml/min) but caused a threefold greater 
decrease in flow (2.9 +-. 0.9 ml/min) in untreated patients (p = 
0.0003, 95% CI for difference between untreated patients and 
control subjects 1.1 to 2.7). These findings suggest increased basal 
endothelium-derived r laxing factor activity in patients with ane- 
mia. Stimulated forearm blood flows (both endothelium depen- 
dent and endothelium independent) were similar in all groups, 
confirming normal endothelial and smooth-muscle function. 
Conclusions. These findings support the hypothesis that en- 
hanced basal endothelium-derived r laxing factor activity makes 
an important contribution to the low systemic vascular esistance 
in chronic severe anemia. 
(J Am Coil Cardiol 1995;25:1402-7~ 
Patients with chronic severe anemia have a high output state 
due to a low systemic vascular resistance, which is rapidly 
corrected after treatment (1,2). Although its pathogenesis 
remains unclear, low systemic vascular esistance has impor- 
tant implications. We have shown (2,3) that low systemic 
vascular esistance and not myocardial dysfunction is the major 
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factor that mediates alt and water retention in various syn. 
dromes of high output congestive heart failure. Two major 
factors have been suggested to contribute to the low systemic 
vascular esistance in anemia: reduced viscosity and peripheral 
vasodilation. The cause of peripheral vasodilation has re- 
mained unexplained. In recent years, endothelium-derived 
relaxing factor or nitric oxide has been shown to play an 
important role in the regulation of vascular tone and arterial 
blood pressure (4,5). Because hemoglobin is a potent inhibitor 
of endothelium-derived relaxing factor (6), we postulated that 
in chronic severe anemia low circulating hemoglobin results in 
reduced inhibition of endothelium-derived r laxing factor. The 
basal endothelium-derived relaxing factor activity therefore 
increases, and this accounts for the generalized vasodilation 
and the high output state (7). In this report, we present data to 
support his hypothesis. 
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Methods  
Patients. The study was carried out at the Dayanand 
Medical College and Hospitals, Ludhiana, India, in eight male 
patients (mean [+_SO] body surface area 1.55 +_ 0.I m 2) with 
chronic severe anemia who presented with symptoms of fatigue 
and shortness of breath (New York Heart Association func- 
tional class III). The jugular venous pressure was not elevated, 
but most patients had mild ankle edema. Chest radiographic 
findings were normal. The electrocardiogram (ECG) showed 
nonspecific ST segment and T wave changes. Anemia was due 
to hookworm infection in three, chronic bleeding piles in two, 
idiopathic aplastic anemia in one and nutritional deficiency in 
two. Routine clinical chemistry, serum creatinine l vels, liver 
function tests and serum albumin levels were normal. None of 
the patients had received any treatment for anemia or heart 
failure. Six patients were restudied after rapid transfusion 
(4.5 +_ 0.5 U) of packed red blood cells. Six age-matched 
normal male subjects (body surface area 1.54 +_ 0.06 m 2) were 
studied as control subjects. The study was approved by the 
Dayanand Medical College and Hospitals Human Studies 
Committee inJuly 1992, and all subjects gave written informed 
consent to the procedure. 
Protocol. After initial forearm blood flow measurements, 
the anemic patients underwent a hemodynamic study. They 
then received transfusion of packed red blood cells over the 
next 12-16 h to increase their hematocrit to -30%. Forearm 
blood flow studies and hemodynamic measurements were 
repeated at the end of transfusion at an average of 24 h after 
the first study. Hemodynamic measurements were not made in 
the control subjects, and forearm blood flow was studied only 
once in these subjects. 
Forearm blood flow. Studies were performed in the morn- 
ing in a quiet temperature-controlled room with the subjects 
laying supine. An 18-gauge cannula was inserted into the 
brachial artery of the nondominant arm, and forearm blood 
flow (ml/100 ml forearm volume per min) was measured inthat 
arm using a mercury-in-rubber strain gauge plethysmograph 
(model EC5; D.E. Hokanson) (8,9). All flow measurements 
were made during intraarterial infusion of either 5%, dextrose 
in water or drug at 1 ml/min. Blood pressure was recorded 
from the intraarterial catheter and heart rate from the ECG 
monitor during each measurement. 
After obtaining baseline measurements with 5% dextrose, 
we measured forearm blood flow during infusion of either an 
endothelium-dependent vasodilator (methacholine) or an 
endothelium-independent vasodilator (sodium nitroprusside). 
Methacholine was infused in two cumulative doses of 0.3 and 
1.5 txg/min. Sodium nitroprusside was infused at 1 and 5 ixg/min. 
These doses have been shown to produce comparable in- 
creases in blood flow in normal subjects (9). Each dose was 
infused for 3 min, and forearm blood flow was measured 
during the last minute of the infusion. A 20-rain rest period was 
allowed between infusion of the two drugs to allow flow to 
return to the basal level, and a control measurement was 
obtained before infusion of the second drug. After testing the 
responses to methacholine and nitroprusside, a further 20-rain 
period was allowed for return of flow to basal values. The 
arginine analogue NG-monomethyl-L-arginine, an inhibitor of 
nitric oxide (5), was then infused at 4 and 16 ixmol/min 
(infusion rate 1 ml/ml) for 4 min each, and during the last 
minute of each infusion flow measurements were repeated. At 
the end of these measurements, N~-monomethyl-L-arginine 
infusion was continued and the effects of 1.5 /xg/min metha- 
choline and 5 tzg/min sodium nitroprusside were tested, with 
rest periods between the drugs. The sequence of administra- 
tion of methacholine and sodium nitroprusside before and 
after infusion of NG-monomethyl-L-arginine was randomized 
and the subjects were not aware of which drug was being 
infused. 
Hemodynamic variables. Right heart catheterization was 
performed with a Swan-Ganz thermodilution balloon catheter. 
Arterial pressure was measured from the intraarterial brachial 
cannula. Pressures were measured with Hewlett-Packard 
1290C quartz transducers and a Hewlett-Packard 7835A mon- 
itor. Cardiac output was determined by thermodilution (model 
SP 1445, Gould). 
Statistics. Results are presented as mean value ± SD. 
Differences in basal flow between the control and the two 
anemic groups were analyzed using the unpaired t test; differ- 
ences between the untreated and treated anemic groups were 
compared using the paired t test. The effect of multiple 
comparisons was adjusted using the Bonferroni correction. 
The effects of drug interventions (multiple doses of N G- 
monomethyl+-arginine, m thacholine and nitroprusside) in 
various groups were compared using the two-way fixed-effects 
univariate analysis of variance for repeated measurements, and 
the p values were corrected with the Greenhouse-Geisser 
correction. For comparisons between the patients (untreated 
or treated) and control subjects, we used one between-group 
factor (group) and one within-group factor (drug dose with 
multiple levels). For comparisons between the patient groups 
(untreated vs. treated), two within-group factors were used 
(group with two levels and drug dose with multiple levels). The 
interaction term (group × dose) was used to assess the 
differences in the effect of an intervention among the various 
groups. All the analyses were done using the multivariate 
analysis of variance module in a commercial statistical program 
(STATISTICA, StatSoft Inc., 1994); p < 0.01 was considered 
significant. 
Resu l ts  
The patients and normal control subjects were of similar 
age (33 ± 15 vs. 33 +. 9 years, respectively). Hemoglobin and 
hematocrit (4.8 _ 0.7 g/dl and 16 +. 2%) were significantly 
lower in patients than in control subjects (13.0 +. 0.5 g/dl and 
40 _+ 1%, p < 0.001). After blood transfusion, hemoglobin and 
hematocrit increased significantly inthe patients (9.6 +. 0.7 g/dl 
and 30 + 1.0%, p < 0.001) but remained lower than that in the 
control subjects (p < 0.001). 
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Table 1. Basal and Stimulated Forearm Blood Flow (mean -+ SD) in Patients With Chronic Severe 
Anemia Before and After Treatment and in Normal Control Subjects 
Untreated Anemia Treated Anemia Control Subjects 
(n=8) (n=6) (n=6) 
Hemoglobin (g/dl) 4.8 ± 0.7*t 9.6 ± 0.7* 13.0 _+ 0.5 
Hematocrit (%) 16 ± 2*t 30 -- 1' 40 ± 1 
Hemodynamic variables 
Heart rate 86 ~- 14 68 : 7 60 _+ 12 
Mean right atrial pressure (ram Hg) 3 ± 1 1 ± 1 
Mean pulmonary artery pressure (mm Hg) 11 _+ 3 8 ± 2 
Mean pulmonary wedge pressure (ram Hg) 5 _+ 3 4 + 2 
Mean arterial pressure (mm Hg) 74 _+ 8*? 85 ± 7* 94 = 4 
Cardiac output (liters/rain per m 2) 4.9 + 0.6? 3.5 +_ 0.5 
Systemic vascular resistance (dynes.s.cm 5) 796 _+ 1417 1,230 _+ 151 
Forearm blood flow (ml/min per 100 ml vol) 
Baseline flow 6.5 _+ 1.2"t 3.5 -+ 1.1~ 2.8 -+ 0.7 
Peak flow with 
Mch 0.3 ,a~/min§ 11.1 _+ 3 9.6 ± 3.4 7.6 ± 4 
Mch 1.5 ~tg/min§ 19.7 : 5.5 18.6 ± 5.6 14.4 ± 6.6 
SNP 1.0 ,ag,/min§ 10.7 ± 2.1 7.0 +_ 2.3 6.6 ± 1.6 
SNP 5.0 gg/min§ 19.1 ± 5.0 18.0 ± 5.9 13.5 ± 4.7 
L-NMMA 4 t~M/minll 5.0 ± 0.9 3.0 ± 1.0 2.2 ,+ 0.5 
L-NMMA 16 ~M/minll 3.6 ± 0.8 2.5 ,+ 0.9 1.8 ,+ 0.4 
L-NMMA 16 txM/min + Mch 1.5/zg/min¶ 12.7 _+ 4.7 10.6 + 3.7 7.8 ,+ 4.2 
L-NMMA 16 ~M/min + SNP 5.0/~g/min¶ 17.9 + 6.4 14.3 ± 4.1 11.5 : 3.4 
Change in flow (peak baseline) with 
Mch 0.3/zb'min§ 4.6 + 2.7 6.1 ,+ 2.7 4.8 ± 1.6 
Mch 1.5/zg/min§ 13.2 +_ 4.9 15.1 ,+ 4.8 11.7 _+ 6.8 
SNP 1.0/zgJmin§ 4.2 + 2.1 3.5 ± 1.9 3.8 ,+ 1.8 
SNP 5.0 ~tb'min§ 12.6 ± 4.0 14.5 ,+ 5.0 10.7 -+ 5.0 
L-NMMA 4/xM/minll -1.5 ± 0.8 -1.0 ,+ 1.1 -0.6 ,+ 0.2 
L-NMMA 16/zM/minll -2.9 "__ 0.9 -1.0 = 0.8 -1.0 -+ 0.4 
L-NMMA 16 ~tM/min + Mch 1.5 txg/minSl 6.2 _+ 4.5 7.0 ,+ 3.2 5.1 ± 4.2 
L-NMMA 16 gM/min + SNP 5.0 gg/min¶ 11.4 ± 5.5 10.8 ,+ 3.2 8.7 _+ 3.8 
*p < 0.001 versus control. ]p < 0.001 versus treated. ~p - NS versus control. §All (group x drug) interaction among 
groups, p - NS by analysis of variance. IIUntreated versus control or treated (group x drug) interaction, p < 0.001; 
treated versus control, p = NS. ¶p = NS among all groups. Data presented are mean value - SD. L-NMMA = 
NG-monomethyl-L-arginine; Mch = methacholine; SNP - sodium nitroprusside. 
Hemodynamic variables (Table 1). Rest heart rate was 
86 _+ 14 beats/min; right atrial pressure (3 _+ 1 mm Hg), mean 
pulmonary artery pressure (11 _+ 3 mm Hg) and mean pulmo- 
nary wedge pressure (5 _+ 3 mm Hg) were within normal imits. 
Cardiac output was high (4.9 ,+ 0.6 liters/min per m 2) but mean 
arterial blood pressure (74 ,+ 8 mm Hg) and systemic vascular 
resistance (796 _+ 141 dynes.s.cm -5) were low. After blood 
transfusion, heart rate (68 ,+ 7 beats/min, p < 0.05) and cardiac 
output (3.5 _+ 0.5 liters/rain per m2; p < 0.001) decreased, and 
systemic vascular resistance (1,230 ,+ 151 dynes.s.cm 5, p < 
0.001) increased, 
Forearm blood flow studies. The primary a priori hypoth- 
esis in this study was that an excess of basal endothelium- 
derived relaxing factor is important in the pathogenesis of 
reduced systemic vascular esistance. This was tested by com- 
paring the effects of N6-monomethyl-L-arginine and correc- 
tion of anemia on baseline blood flow. 
Basal forearm blood flow (Fig. 1, Table 1). Basal forearm 
blood flow in the anemic subjects was 6.5 ,+ 1.2 ml/100 ml 
forearm volume per min, more than twice that seen in the 
control subjects (2.8 _+ 0.7 ml/100 ml forearm volume per min, 
p < 0.0001, 95% confidence interval [CI] for difference -5  to 
-2.5).  Blood transfusion significantly reduced blood flow in 
the anemic patients to 3.5 _+ 1.1 ml/100 ml forearm volume per 
min (p = 0.002, 95% CI for difference -4 .9 to -1.9),  and this 
value was not significantly different from that the control 
subjects (p = 0.19, 95% CI for difference -1 .8 to 0.4). 
Effect of NC-monomethyl-L-arginine. NG-monomethyl-L - 
arginine caused a dose-dependent decrease in basal forearm 
blood flow in all three groups (Fig. 1 [top], Table 1). Although 
the dose response to NG-monomethyl-L-arginine was similar in 
the treated and control groups (p -- 0.96 for absolute flow and 
p = 0.78 for change in flow or delta flow), the untreated group 
showed a significantly greater decrease in forearm blood flow 
than either the treated group (p = 0.0003 for absolute flow and 
p = 0.04 for delta flow) or control subjects (p = 0.00001 for 
absolute flow and p = 0.007 for delta flow). Thus, with 16 
/zmol/min N~-monomethyl-L-arginine, forearm blood flow de- 
creased by an equal amount (p = 0.9, 95% CI -0 .7  to 0.8) in 
both control subjects (0.98 _+ 0.39 ml/min) (Fig. 1 [bottom]) 
JACC Vol. 25, No. 6 ANAND ET AL. 1405 









Forearm blood flow 
(ml/min/100rnl Vol) 
• Untreated anemia 
~ =  Treated anemia 
do~treis 
§ 
± t_. '~ 
i i 
Basal L-NMMA L-NMMA 
4 umol/min 16 umol/min 
Forearm blood flow 
(ml/min/100ml Vol) p<0.0Ol 
I Untreated anemia 




Decrease in f low with L -NMMA (16 umol/min)  
Figure 1. Dose-dependent decrease in basal forearm blood flow with 
4 and 16 /smol/min of NC-monomethyl-L-arginine (L-NMMA) in 
treated and untreated patients with chronic severe anemia (n = 6) and 
in normal control subjects (top). Bars (bottom) show absolute de- 
creases from baseline in basal forearm blood flow with 16 p.mol/min of 
NG-monomethyl-L-arginine in the three groups; p values (top) are by 
analysis of variance (group × dose interaction) with Greenhouse- 
Geisser correction. 
and treated patients (1.03 _+ 0.8 ml/min) Fig. 1 [bottom]. In 
contrast, the same dose of NG-monomethyl-L-arginine caused 
a nearly threefold greater decrease in flow (2.9 _+ 0.9 ml/min) 
(Fig. 1 [bottom]) in the untreated patients (p = 0.0003, 95% CI 
for difference between untreated and control subjects 1.1 to 
2.7). Both doses of N°-monomethyl-L-arginine had no effect 
on the systemic arterial blood pressure. For this reason the 
forearm vascular esistance data are not shown because they 
mirrored the blood flow changes. 
Effects of endothelium-dependent and endothelium. 
independent vasodilators on stimulated forearm blood flow 
(Table 1). An ancillary interest of this study, not primarily 
related to the central hypothesis, was to investigate the endo- 
thelial and vascular smooth-muscle function in these patients 
to see whether this contributes to the differences in blood flow. 
This was done by testing the effects of multiple doses of 
endothelium-dependent a d endothelium-independent vaso- 
dilators. 
Both methacholine (Fig. 2 [top], Table 1) and sodium 
nitroprusside (Table 1) caused a dose-dependent increase in 
blood flow in control subjects and in untreated and treated 
anemic patients. Although absolute basal flows were different, 
the increases in flow with the two doses of methacholine (0.3 
25 Forearm blood flow 
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20 1 • Treated 
15t l  C o n ~  
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+ L-NMMA flow with L-NMMA 
(Peak flow - Basal flow) __1  
Figure 2. Effect of the endothelium-dependent vasodilator methacho- 
line (Mch) on forearm blood flow in normal control subjects and in 
patients with chronic severe anemia before and after treatment. Top, 
Basal and peak stimulated flow with methacholine (0.3 and 1.5 ~g/min) 
and the effect of NC-monomethyl-L-arginine (L-NMMA) (16 txmol/ 
min) on the methacholine-l.5-stimulated flow.Bottom, Increase (peak -
basal) in flow with methacholine (0.3 and 1.5/zg/min) and methacholine 
1.5 plus N~-monomethyl-L-arginine. Th  last group of bars shows the 
decrease inmethacholine-l.5-stimulated blood flow after administration 
of NG-monomethyl-L-arginine (16 txmol/min). *p < 0.001 for baseline 
flow, untreated versus control; #p < 0.001 for baseline flow, untreated 
versus treated. 
and 1.5 ug/min) (Fig. 2 [bottom]) and sodium nitroprusside 
were similar in the three groups (interaction between group × 
methacholine: p = 0.34 between untreated and control sub- 
jects, p = 0.43 for treated vs. control subjects and p = 0.73 for 
untreated vs. treated groups; interaction between group × 
sodium nitroprusside: p = 0.40 between untreated and control 
subjects, p = 0.16 for treated vs. control subjects and p = 0.69 
for untreated vs. treated groups). The doses of methacholine 
and sodium nitroprusside used in these experiments had no 
effect on arterial blood pressure. 
Effect of N~-monomethyl-L-arginine on methacholine- and 
sodium nitroprusside-stimulated forearm blood flow (Table 
1). NG-monomethyl-L-arginine infusion (16/xmol/min) caused 
a significant reduction in the methacholine (1.5 ~g/min)- 
stimulated blood flow in all three groups (Fig. 2 [top]). The 
reductions in methacholine-stimulated flow caused by N G- 
monomethyl-L-arginine fusion were similar in the untreated 
anemic patients (7 _+ 5 ml), treated anemic patients (8 + 
3.4 ml) and control subjects (6.7 + 6 ml) (untreated vs. control 
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subjects p = 0.9, 95% CI for difference -7.5 to 6.7; untreated 
vs. treated p = 0.9, 95% CI for difference -6.2 to 7, treated vs. 
controls p = 0.7, 95% CI for difference -8.8 to 6; Fig. 2 
[bottom]). In contrast, N°-monomethyl-L-arginine caused only 
a minimal decrease in the sodium nitroprusside-stimulated 
flow which too was no different among the three groups. 
Discuss ion  
The present study investigated only those patients with 
chronic severe anemia who did not have evidence of congestive 
heart failure because heart failure could itself alter endothelial 
responses (9). Hernodynamic measurements in these patients 
were classic of a hyperdynamic state with high cardiac output 
and low systemic vascular esistance (1,2). The hyperdynamic 
circulation was accompanied by an increased forearm blood 
flow and reduced forearm vascular esistance. Rapid correc- 
tion of anemia with packed cell transfusion over 24 h reduced 
cardiac output, increased systemic vascular resistance and 
corrected the hyperdynamic state. The forearm blood flow and 
forearm vascular esistance became normal. 
Possible mechanisms for vasodilation in severe anemia. 
The mechanisms responsible for the low systemic vascular 
resistance in chronic severe anemia remain unknown (1,2). 
Low viscosity due to reduced hematocrit contributes to but 
cannot entirely explain the low systemic vascular esistance 
(7,10). Tissue hypoxia is not a direct cause of low systemic 
vascular esistance, as partial pressure oxygen is normal in 
anemia nd reducing the arterial oxygen content in dogs by 
inducing methemoglobinemia to levels seen in chronic severe 
anemia does not affect the systemic vascular esistance (11). 
Hemoglobin is a potent inhibitor of endothelium-derived 
relaxing factor (6). There is also evidence that hemoglobin 
affects vascular resistance in vivo: Infusion of stroma-free 
hemoglobin causes an immediate and pronounced increase in 
systemic vascular resistance in hemorrhagic shock (12), a 
condition in which systemic vascular resistance isalready high. 
This effect is in contrast o a decrease in systemic vascular 
resistance seen with the use of non-blood volume expanders 
(12). Is hemoglobin in red blood cells also accessible to 
endothelium-derived relaxing factor in the vascular lumen? A 
number of lines of evidence suggest hat hemoglobin i  the 
intact red blood cell does influence luminal endothelium- 
derived relaxing factor. First, endothelium-derived r laxing 
factor is highly diffusable across membranes and hemoglobin 
has a great affinity for endothelium-derived r laxing factor 
(13). Second, Gillespie and Sheng (14) have shown that 
hemoglobin in intact red blood cells is as effective as free 
hemoglobin i  blocking endothelium-dependent vasodilation. 
Finally, whole blood with a hemoglobin concentration as low as 
1 g/dl can block some of the circulating nitric oxide (15). 
Therefore, we postulated that the low circulating hemoglobin 
in patients with chronic severe anemia results in reduced 
inhibition of vascular endothelium-derived r laxing factor, 
which then contributes tothe vasodilation and the high output 
state. 
Our findings support this hypothesis. In the untreated 
anemic patients, increased forearm blood flow and low fore- 
arm vascular esistance were rapidly corrected by both endo- 
genous (hemoglobin) and exogenous (N6-monomethyk - 
arginine) inhibitors of endothelium-derived r laxing factor. 
The effect of N%monomethyl-L-arginine was dose dependent, 
and the higher dose reduced the forearm blood flow to the 
same extent as seen by increasing hemoglobin to 9 g/dl. The 
degree of reduction in forearm blood flow with N c- 
monomethyl-L-arginine is a measure of the contribution made 
by endothelium-derived r laxing factor to basal vascular tone 
(16); a greater decrease in blood flow with N6-monomethyl - 
L-arginine implies a higher concentration at the vascular 
surface (17). N°-monomethyl-L-arginine (16 /xmol/min) 
caused a similar (-1 ml/min) decrease in basal blood flow in 
control subjects and treated patients (Fig. 1 [bottom]). In 
contrast, the same dose of N°-monomethyl-L-arginine caused 
a threefold greater decrease (2.9 ml/min) in flow in untreated 
patients. This suggests hat the extra flow (-2 ml/min) reduced 
by the same dose of N°-monomethyl-L-arginine in the untreated 
patients was probably caused by an excess of endothelium- 
derived relaxing factor that N6-monomethyl-l.-arginine was 
able to block. Even during N6-monomethyl-L-arginine fu- 
sion, forearm blood flow in untreated patients (3.6 +_ 
0.8 ml/min) remained -1 ml/min higher than that in the 
treated patients (2.5 + 0.9 ml/min). This amount of forearm 
blood flow could be attributed to non-endothelium-derived 
relaxing factor-dependent mediators and gives an estimate of 
the contribution made by factors uch as viscosity and other 
non-endothelium-derived relaxing factor mechanisms. How- 
ever, it could be argued that the concentration of N ~- 
monomethyl-L-arginine us d in this study was not sufficient to 
block all the excess nitric oxide and that higher concentrations 
might have reduced basal forearm flow further, to levels seen 
in treated patients. Although this would further favor the 
endothelium-derived r laxing factor hypothesis, it is unlikely 
that a higher concentration of NG-monomethyl-L-arginine 
would have decreased flow further because the same concen- 
tration of NC-monomethyl+-arginine (16 ~mol/min) reduced 
methacholine (1.5 txg/min)-stimulated flow by a much greater 
amount (19.7 +_ 5.5 to 12.7 +_ 4.7 ml/min) in the untreated 
patients, suggesting that the dose of N°-monomethyl-I. - 
arginine used in our study was sufficient to block most of the 
basal circulating endothelium-derived r laxing factor. Thus, 
the residual increase in flow is most likely non-endothelium- 
derived relaxing factor-dependent. These findings uggest that 
enhanced endothelium-derived r laxing factor activity, be- 
cause of its reduced inhibition by low circulating hemoglobin, 
contributes substantially tothe low systemic vascular resistance 
in anemia. However, it is unclear whether these patients also 
have increased synthesis and release of nitric oxide. High blood 
flow increases hear stress and therefore nitric oxide release 
(18), but low hematocrit has the opposite ffect on shear stress. 
Therefore the net effect of anemia on the flow-mediated nitric 
oxide release is difficult o assess, and our study was not de- 
signed to address this. 
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Endothelial and smooth-muscle function in severe anemia. 
Although the basal forearm blood flow was significantly in- 
creased in the untreated patients, both endothelium- 
dependent and endothelium-independent vasodilators caused 
a further increase in flow almost identical to that seen in 
normal subjects or treated patients, albeit from a higher 
baseline level (Fig. 2 [bottom], Table 1). These data are 
consistent with the findings in simulated septicemic shock, a 
condition associated with increased nitric oxide in which the 
arteriolar esponse to endothelium-dependent vasodilators 
remains normal unless accompanied bystructural endothelial 
damage (19). This suggests that both the endothelial function 
and the ability of vascular smooth muscle to respond to 
guanylate cyclase-mediated vasodilation are normal in patients 
with chronic severe anemia. Although this would explain the 
similar increases in stimulated flow in all groups, we were 
surprised that the anemic group did not have a higher stimu- 
lated flow. There was a trend toward higher stimulated flows 
but the wide standard eviation resulted in a lack of a sta- 
tistically significant difference. 
Conclusions and implications. Low systemic vascular e- 
sistance, which is the hallmark of chronic severe anemia nd 
other conditions with a hyperdynamic circulation, such as cor 
pulmonale, may have important pathogenetic mplications 
(2,3). We have shown that salt and water retention in the 
syndromes of both low and high output congestive heart failure 
is due to reduced renal blood flow as a result of neurohumoral 
activation (2,3,20). The stimulus for neurohumoral ctivation 
appears to be a threat o arterial blood pressure (21). In low 
output congestive heart failure blood pressure is threatened 
because of reduced cardiac output. However, in high output 
congestive heart failure cardiac output is normal or increased, 
and blood pressure is threatened because of low systemic 
vascular esistance. ]"he present study suggests that patients 
with chronic severe anemia have increased endothelium- 
derived relaxing factor activity due to its reduced inhibition by 
low hemoglobin, and this contributes significantly to the low 
systemic vascular esistance. 
We thank Dr. Tom Rector, PhD for assistance with statistical analysis. 
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